Form 4 for ELVN Enliven Therapeutics, Inc.

Accepted 2025-11-21 00:00:00 ET · period of report 2025-11-19 · accession 0001967150-25-000007 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2025-11-21	2025-11-19	ELVN	Lyssikatos Joseph P	CSO	S - Sale	$22.33	-12.5K	902.7K	-1%	-$279.1K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-11-19	S	D	12,008	$22.30	903,180	I See footnote	—	—	(F2) This transaction was executed in multiple trades at prices ranging from $22.035 to $23.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
2	Common	Common Stock	2025-11-19	S	D	492	$23.09	902,688	I See footnote	—	—	(F4) This transaction was executed in multiple trades at prices ranging from $23.045 to $23.165. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.